Dysport® Injection in the Treatment of Chronic Lateral Epicondylitis (DCLE)
This study has been completed.
Sponsor:
Tehran University of Medical Sciences
Information provided by:
Tehran University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00497913
First received: July 6, 2007
Last updated: April 22, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether a single injection of Dysport with a new protocol at forearm is effective in the management of chronic lateral epicondylitis.
| Condition | Intervention | Phase |
|---|---|---|
|
Tennis Elbow |
Drug: NaCl 0.9% Drug: Botulinum Toxin A |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Tehran University of Medical Sciences:
Primary Outcome Measures:
- Pain score on VAS at maximal grip, at maximal pinch, and during previous month at rest [ Time Frame: 4 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Patients subjective feeling of improvement. [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Tenderness on lateral epicondyle [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Pain sensation on resisted wrist extension, and passive wrist flexion [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Pain-free grip strength, and pinch strength [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Maximal grip strength, and pinch strength [ Time Frame: 4 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 52 |
| Study Start Date: | August 2007 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: A |
Drug: Botulinum Toxin A
Other Name: Dysport
|
| Placebo Comparator: B | Drug: NaCl 0.9% |
Detailed Description:
Some studies valued the effectiveness of botulinum toxin. There is a great amount of controversy on the amount of botulinum toxin injected and the location of the injection. The purpose of the study is to compare the effectiveness of botulinum toxin injection with placebo at a new injection site at the forearm in the treatment of chronic tennis elbow unrelieved by corticosteroid injection and physiotherapy. It is a double blind randomized controlled trial.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Pain: pain will be assessed as the physician touches lateral epicondyle or passively flexing the patient's wrist and while the patient extends his/her wrist or 3rd finger against resistance. Individuals who fulfill two or more of above will be considered to have lateral epicondylitis.
- Symptom duration: should be at least 6 months.
- Previous trial of complete course of physiotherapy and corticosteroid injection.
Exclusion Criteria:
- Rheumatoid arthritis
- Generalized polyarthritis
- Local elbow arthritis
- Simultaneous medial epicondylalgia
- Bilateral lateral epicondylitis
- Neurologic deficits (abnormal light touch sensation, deep tendon reflexes abnormality, radicular pain, radial nerve entrapment, signs of nerve root compression, decreased muscle force, multiple sclerosis, seizures)
- The use of corticosteroid in last 30 days
- Simultaneous use of drugs other than acetaminophen or physical therapy in the course of study
- Pregnancy
- Breast-feeding
- Previous hand surgery
- Having a hobby or job that needs finger extension
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00497913
Locations
| Iran, Islamic Republic of | |
| Imam Khomeini Hospital | |
| Tehran, Iran, Islamic Republic of, 1419173341 | |
Sponsors and Collaborators
Tehran University of Medical Sciences
Investigators
| Study Director: | Seyed Mohammad J Mortazavi, M.D. | Tehran University of Medical Sciences |
More Information
No publications provided by Tehran University of Medical Sciences
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00497913 History of Changes |
| Other Study ID Numbers: | 85-02-53-4207 |
| Study First Received: | July 6, 2007 |
| Last Updated: | April 22, 2008 |
| Health Authority: | Iran: Ministry of Health |
Keywords provided by Tehran University of Medical Sciences:
|
Tennis Elbow Botulinum Toxin |
Additional relevant MeSH terms:
|
Tennis Elbow Musculoskeletal Diseases Arm Injuries Wounds and Injuries Botulinum Toxins, Type A Botulinum Toxins Neuromuscular Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Dyskinesia Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013